Edward Mathers is Partner at New Enterprise Associates, Inc. (NEA), a private venture capital firm focusing on technology and healthcare investments. Mr. Mathers serves on the board of directors of Trevi Therapeutics, Inc. (NASDAQ: TRVI), Inozyme Pharma, Inc. (NASDAQ: INZY), Rhythm Pharmaceuticals, Inc. (FSE: 1RV.F), Synlogic, Inc. (NASDAQ: SYBX), Senti Biosciences, Inc. (NASDAQ: SNTI) and MBX Biosciences (NASDAQ: MBX). Mr. Mathers previously served on the board of directors of ObsEva SA, Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), Akouos, Inc., Liquidia Technologies, Inc., Lumos Pharma, Inc., Ra Pharmaceuticals, Inc., and Reneo Pharmaceuticals, Inc.
Prior to joining NEA, Mr. Mathers previously served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., and led its venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune, Mr. Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Previously, Mr. Mathers spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held various sales and marketing positions. Mr. Mathers received a B.S. in Chemistry from North Carolina State University.